Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers

Abstract Head and neck cancer (HNC) is the seventh most common cancer worldwide. Currently-approved systemic therapies include chemotherapy, anti-EGFR antibodies, and PD-1 immunotherapy, with few genomic-based targeted therapies. Gene fusions involving cancer-driving kinase genes such as FGFR, NTRK,...

Descrición completa

Detalles Bibliográficos

Principais autores:	Emily L. Hoskins, Raven Vella, Julie W. Reeser, Michele R. Wing, Eric Samorodnitsky, Altan Turkoglu, Leah Stein, Elizabeth Breuning, Zachary A. Risch, Wilnelly M. Hernandez-Sanchez, Lianbo Yu, Michelle Churchman, Nancy Single, Jad Chahoud, Antonio Jimeno, Michael J. Cavnar, Matthew Reilley, Courtney Scaife, Kenneth G. Nepple, Minh Phan, Bryan Schneider, Stephen Edge, Bodour Salhia, Aliza Leiser, Trisha M. Wise-Draper, Michael K. Wendt, Sameek Roychowdhury
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2025-07-01
Series:	npj Precision Oncology
Acceso en liña:	https://doi.org/10.1038/s41698-025-00889-7
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!